Abstract
Most gastrointestinal stromal tumors (GISTs) express constitutively activated forms of the KIT receptor tyrosine kinase protein, resulting from oncogenic mutations in the extracellular, juxtamembrane, or kinase domains. KIT oncoproteins are detected early in GIST tumorigenesis, and most GIST patients respond well to treatment with the KIT kinase inhibitor imatinib mesylate (STI571, GleevecĀ®). However, GISTs can develop resistance to imatinib, and additional therapeutic strategies are needed. Little is known about oncogenic KIT signal transduction in GISTs, and whether the type of KIT mutation accounts for selective activation of downstream signaling intermediates. We therefore evaluated KIT downstream signaling profiles in 15 primary GISTs with mutations in KIT exons 9, 11, 13, and 17, and in two human GIST cell lines. All GISTs showed constitutive phosphorylation at KIT tyrosine residues Y703 and Y721. Additionally, most GISTs showed activation of MAPK p42/44, AKT, S6K, STAT1, and STAT3. STAT5 and JNK were not demonstrably activated in any GIST. Using GIST in vitro models, we showed that activation of MAPK p42/44, AKT, and S6K was KIT dependent, whereas STAT1 and STAT3 phosphorylation was only partially dependent on KIT activation. Correlation of activated signaling pathways with the type of KIT mutation revealed low levels of AKT phosphorylation in exon 9 mutant GISTs in contrast to a subset of GISTs with exon 11 mutations. However, additional factors are likely to modify the engagement of signaling pathways in GISTs as suggested by the fact that four GISTs with identical KIT exon 9 mutations had differential activation of MAPK p42/44 and STAT proteins. In summary, in this first report on KIT signal transduction in primary GISTs and GIST cell lines, we identified pathways that are constitutively activated in a KIT-dependent manner and therefore warrant further study as molecular targets in GISTs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C and Larizza L . (2001). Cancer, 92, 657ā662.
Blume-Jensen P, Janknecht R and Hunter T . (1998). Curr. Biol., 8, 779ā782.
Brizzi MF, Dentelli P, Rosso A, Yarden Y and Pegoraro L . (1999). J. Biol. Chem., 274, 16965ā16972.
Caruana G, Cambareri AC and Ashman LK . (1999). Oncogene, 18, 5573ā5581.
Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, Lecocq E, Rottapel R and Dubreuil P . (2003). Oncogene, 22, 4710ā4722.
Chen H, Isozaki K, Kinoshita K, Ohashi A, Shinomura Y, Matsuzawa Y, Kitamura Y and Hirota S . (2003). Int. J. Cancer, 105, 130ā135.
Chian R, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, Ferrao P, Ashman L and Linnekin D . (2001). Blood, 98, 1365ā1373.
Corless CL, McGreevey L, Haley A, Town A and Heinrich MC . (2002). Am. J. Pathol., 160, 1567ā1572.
De Miguel MP, Cheng L, Holland EC, Federspiel MJ and Donovan PJ . (2002). Proc. Natl. Acad. Sci. USA, 99, 10458ā10463.
Deberry C, Mou S and Linnekin D . (1997). Biochem. J., 327 (Part 1), 73ā80.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD and Joensuu H . (2002). N. Engl. J. Med., 347, 472ā480.
Dolci S, Pellegrini M, Di Agostino S, Geremia R and Rossi P . (2001). J. Biol. Chem., 276, 40225ā40233.
Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH and O'Leary TJ . (1998). Lab. Invest., 78, 1633ā1636.
Feng LX, Ravindranath N and Dym M . (2000). J. Biol. Chem., 275, 25572ā25576.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH and Weiss SW . (2002). Hum. Pathol., 33, 459ā465.
Frost MJ, Ferrao PT, Hughes TP and Ashman LK . (2002). Mol. Cancer Ther., 1, 1115ā1124.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S and Fletcher JA . (2003a). J. Clin. Oncol., 21, 4342ā4349.
Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA . (2003b). Science, 299, 708ā710.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y . (1998). Science, 279, 577ā580.
Hirota S, Okazaki T, Kitamura Y, O'Brien P, Kapusta L and Dardick I . (2000). Am. J. Surg. Pathol., 24, 326ā327.
Hornick JL and Fletcher CD . (2002). Am. J. Clin. Pathol., 117, 188ā193.
Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB and Bernstein A . (1995). Nature, 373, 347ā349.
Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S and Vanderwinden JM . (2000). Am. J. Pathol., 157, 1581ā1585.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B and Demetri GD . (2001). N. Engl. J. Med., 344, 1052ā1056.
Kindblom LG, Remotti HE, Aldenborg F and Meis-Kindblom JM . (1998). Am. J. Pathol., 152, 1259ā1269.
Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE and Skorski T . (2002). EMBO J., 21, 5766ā5774.
Lai CF, Ripperger J, Morella KK, Wang Y, Gearing DP, Horseman ND, Campos SP, Fey GH and Baumann H . (1995). J. Biol. Chem., 270, 23254ā23257.
Lasota J, Jasinski M, Sarlomo-Rikala M and Miettinen M . (1999). Am. J. Pathol., 154, 53ā60.
Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M and Ronnstrand L . (1999). Oncogene, 18, 5546ā5553.
Lev S, Givol D and Yarden Y . (1992). Proc. Natl. Acad. Sci. USA, 89, 678ā682.
Linnekin D . (1999). Int. J. Biochem. Cell Biol., 31, 1053ā1074.
Linnekin D, Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK and Longo DL . (1996). Acta Haematol., 95, 224ā228.
Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD and Fletcher JA . (2000). Am. J. Pathol., 156, 791ā795.
Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y and Katsuyama T . (2001). Gastroenterology, 120, 210ā215.
Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA and Skorski T . (2002). Blood, 99, 4531ā4539.
Ning ZQ, Li J and Arceci RJ . (2001a). Leuk. Lymphoma, 41, 513ā522.
Ning ZQ, Li J and Arceci RJ . (2001b). Blood, 97, 3559ā3567.
Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H and Kitamura Y . (1998). Nat. Genet., 19, 323ā324.
Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD and Fletcher JA . (2001). Cancer Res., 61, 8118ā8121.
Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I and Riddell RH . (1999). Am. J. Surg. Pathol., 23, 377ā389.
Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR and Besmer P . (2003). Proc. Natl. Acad. Sci. USA, 100, 6706ā6711.
Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H and Kitamura Y . (1999). Cancer Res., 59, 4297ā4300.
Taylor ML and Metcalfe DD . (2000). Hematol. Oncol. Clin. North Am., 14, 517ā535.
Thommes K, Lennartsson J, Carlberg M and Ronnstrand L . (1999). Biochem. J., 341 (Part 1), 211ā216.
Tsai M, Chen RH, Tam SY, Blenis J and Galli SJ . (1993). Eur. J. Immunol., 23, 3286ā3291.
Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD . (2001). Oncogene, 20, 5054ā5058.
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato dP, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S and Nielsen OS . (2001). Lancet, 358, 1421ā1423.
Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK and Ronnstrand L . (2003). J. Biol. Chem., 278, 9159ā9166.
Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK, Longo DL and Linnekin D . (1996). Blood, 87, 3688ā3693.
Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, Fisher DZ and Fisher DE . (2000). Genes Dev., 14, 301ā312.
Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U and Ullrich A . (1987). EMBO J., 6, 3341ā3351.
Acknowledgements
We thank Stefan Duensing, Christopher Corless, and Michael Heinrich for review of the manuscript and valuable discussions. AD was supported by a fellowship from the Deutsche Krebshilfe.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Duensing, A., Medeiros, F., McConarty, B. et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999ā4006 (2004). https://doi.org/10.1038/sj.onc.1207525
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207525
Keywords
This article is cited by
-
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Molecular Cancer (2023)
-
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors
Drugs (2023)
-
Molekularpathologisch determinierte multimodale Therapie gastrointestinaler Stromatumoren
Die Onkologie (2023)
-
Molekularpathologisch determinierte multimodale Therapie gastrointestinaler Stromatumoren
Wiener klinisches Magazin (2023)
-
THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours
Cell Communication and Signaling (2022)